A male contraceptive pill is closer to reality, with scientists revealing the capsule has passed initial stages of testing. A month-long study of 40 male participants was conducted by the University of Washington, where users took a once-daily capsule to try and suppress the levels of hormones that contribute to the production of sperm. The researchers found that hormone levels in the men taking the pill fell, with sperm counts notably reduced.
As World Aids Day 2018 takes place, NHS England is facing pressure to begin offering the groundbreaking HIV medicine Pre-Exposure Prophylaxis (PrEP). Administered as a pill under the brand name Truvada, patients in England can currently only receive PrEP without charge as part of the Impact Trial, which began in September 2017 and aims to test its effectiveness on 13,000 people. PrEP sees Truvada given to HIV-negative people before sex to reduce their risk of contracting the infection, the drug combining two antiviral medicines, tenofovir and emtricitabine, long used in HIV treatment.